welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer Therapeutics Obtains Exclusive License to Celiprolol Pivotal Clinical Data from AP-HP
“We have studied celiprolol for nearly two decades in vEDS patients and this is the only drug ever to demonstrate a clinical benefit in a randomized, controlled clinical study,” said Pierre Boutouyrie M.D., Ph.D., co-director of the clinical pharmacology service at the Georges-Pompidou European Hospital AP-HP and Principal Investigator for the celiprolol study. “Having established celiprolol as a standard of care in France for vEDS patients, we are excited to partner with Acer to help bring celiprolol to members of the U.S. patient community who are suffering from this devastating, life-threatening disease.”
expertly curated content related to this topic
-
Regulatory Role of Collagen V in Establishing Mechanical Properties of Tendons and Ligaments is Tissue DependentPatients with classic (type I) Ehlers-Da...
-
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of THC/CBD Spray in Peripheral Neuropathic Pain...BACKGROUND: Peripheral neuropathic pain...
-
Acer Therapeutics Inc.Acer Therapeutics is a biotech company, ...
-
Ehlers-Danlos Society Receives Transformational Gift to Accelerate Genomic Research into Hypermobile EDSThe Ehlers-Danlos Society has announced ...
-
Clair A. Francomano, MDDr. Francomano received her undergraduat...
-
Brad T Tinkle, MD PhDPresident & CEO at Dr. Brad T Tinkle...
-
Jan Dommerholt, PT, DPT, MPS, DAAPMDr. Jan Dommerholt, PT, DPT, MPS, DAAPM,...